- Home
- AUTL
as 03-31-2025 10:31am EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 590.8M | IPO Year: | 2018 |
| Target Price: | $9.15 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.56 - $6.31 | Next Earning Date: | 03-20-2025 |
| Revenue: | $10,120,000 | Revenue Growth: | 496.00% |
| Revenue Growth (this year): | 274.71% | Revenue Growth (next year): | 239.55% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
GuruFocus.com
10 days ago
What To Expect From Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings
GuruFocus.com
10 days ago
Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs
Thomson Reuters StreetEvents
10 days ago
Q4 2024 Autolus Therapeutics PLC Earnings Call
GlobeNewswire
11 days ago
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
GlobeNewswire
25 days ago
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
Insider Monkey
25 days ago
Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now?
GlobeNewswire
a month ago
Autolus Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
2 months ago
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.